These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 32767396)

  • 1. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines for Renal Management: From Imaging to Treatment.
    Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
    Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
    Sun H; Dong Y; Feijen J; Zhong Z
    J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging Bio-Nano Science and Cancer Nanomedicine.
    Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
    ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.
    Gupta M; Agrawal GP; Vyas SP
    Curr Mol Med; 2013 Jan; 13(1):179-204. PubMed ID: 22834834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
    Wang Y; Cai R; Chen C
    Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the Golden Gate toward a
    Jaymand M
    ACS Biomater Sci Eng; 2020 Jan; 6(1):134-166. PubMed ID: 33463213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives and potential applications of nanomedicine in breast and prostate cancer.
    Liu Y; Solomon M; Achilefu S
    Med Res Rev; 2013 Jan; 33(1):3-32. PubMed ID: 23239045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
    Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
    Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy.
    Sun H; Zhang Y; Zhong Z
    Adv Drug Deliv Rev; 2018 Jul; 132():16-32. PubMed ID: 29775625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Nanomedicines in an Evolving Oncology Landscape.
    Guo P; Huang J; Moses MA
    Trends Pharmacol Sci; 2020 Oct; 41(10):730-742. PubMed ID: 32873407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Incorporated Nanomedicines for Cancer Therapy.
    Wu SY; Wu FG; Chen X
    Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brave new world revisited: Focus on nanomedicine.
    Fadeel B; Alexiou C
    Biochem Biophys Res Commun; 2020 Nov; 533(1):36-49. PubMed ID: 32921412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.